BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159-170. [PMID: 18306990 DOI: 10.1007/s00535-007-2134-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Hsueh T, Kao C, Liang C, Chen S, Hung Y, Tsai M. A retrospective analysis of cirrhotic patients receiving Chinese herbal medicine in addition to conventional care: Survival and safety. European Journal of Integrative Medicine 2015;7:143-50. [DOI: 10.1016/j.eujim.2014.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
2 Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, Wang JH, Huang CM, Lee CM, Lin CY, Yen YH, Chiu YC. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer. 2016;138:714-720. [PMID: 26264553 DOI: 10.1002/ijc.29802] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
3 Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59. [PMID: 21883324 DOI: 10.1111/j.1365-2036.2011.04823.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
4 Pinato DJ, Karamanakos G, Ishizuka M, Smirne C, Pirisi M, Kubota K, Sharma R. The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. Liver Int 2015;35:2458-65. [PMID: 25845291 DOI: 10.1111/liv.12841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Park UJ, Kim YH, Kang KJ, Lim TJ. [Risk factors for early recurrence after surgical resection for hepatocellular carcinoma]. Korean J Hepatol. 2008;14:371-380. [PMID: 18815460 DOI: 10.3350/kjhep.2008.14.3.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
6 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
7 Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci. 2013;58:2721-2728. [PMID: 23703450 DOI: 10.1007/s10620-013-2716-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
8 He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL, Zhang BH, Zhang JY. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation. BMC Cancer. 2011;11:492. [PMID: 22107882 DOI: 10.1186/1471-2407-11-492] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
9 Wang W, Feng X, Zhang T, Jin J, Wang S, Liu Y, Song Y, Liu X, Yu Z, Li Y. Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy. Radiat Oncol 2010;5:73. [PMID: 20731853 DOI: 10.1186/1748-717X-5-73] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
10 Liu PH, Hsia CY, Lee YH, Hsu CY, Huang YH, Su CW, Lee RC, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J Surg Oncol. 2015;111:404-409. [PMID: 25643842 DOI: 10.1002/jso.23854] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
11 Bauschke A, Altendorf-Hofmann A, Malessa C, Schüle S, Zanow J, Settmacher U. Which factors affect the long-term survival of patients with hepatocellular carcinoma UICC stage IV? J Cancer Res Clin Oncol 2016;142:2593-601. [PMID: 27630023 DOI: 10.1007/s00432-016-2260-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Yang P, Zeng ZC, Wang BL, Zhang JY, Fan J, Zhou J, Hu Y. The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT). J Cancer 2016;7:1413-20. [PMID: 27471557 DOI: 10.7150/jca.15405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Zhou J, Yan T, Bi X, Zhao H, Huang Z, Zhang Y, Li Y, Feng L, Wang J, Cai J. Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy. Tumour Biol. 2013;34:1061-1070. [PMID: 23322323 DOI: 10.1007/s13277-013-0646-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Gish RG, Lencioni R, Di Bisceglie AM, Raoul J, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;6:173-85. [DOI: 10.1586/egh.11.105] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
15 Lee CW, Chan KM, Lee CF, Yu MC, Lee WC, Wu TJ, Chen MF. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg 2011;34:53-62. [PMID: 21723467 DOI: 10.1016/S1015-9584(11)60020-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
16 Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis. 2013;45:510-515. [PMID: 23218990 DOI: 10.1016/j.dld.2012.10.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
17 Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44 Suppl 19:96-101. [PMID: 19148801 DOI: 10.1007/s00535-008-2258-6] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 10.4] [Reference Citation Analysis]
18 Chen KD, Lin CC, Tsai MC, Huang KT, Chiu KW. Tumor microenvironment mediated by suppression of autophagic flux drives liver malignancy. Biomed J. 2018;41:163-168. [PMID: 30080656 DOI: 10.1016/j.bj.2018.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744-751. [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
20 Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, Yeh YH, Su SC, Chen YC, Chen MK. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1808-1815. [PMID: 20119675 DOI: 10.1245/s10434-009-0904-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
21 Chen Y, Wu Y, Zhang X, Zeng H, Liu Y, Wu Q, Chen Y, Zhu G, Pan Q, Jin L, Guo L, Sun F. Angiopoietin-2 (Ang-2) is a useful serum tumor marker for liver cancer in the Chinese population. Clin Chim Acta. 2018;478:18-27. [PMID: 29253494 DOI: 10.1016/j.cca.2017.12.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
22 Hsiao WD, Peng CY, Chuang PH, Lai HC, Cheng KS, Chou JW, Chen YY, Yu CJ, Feng CL, Su WP, Chen SH, Kao JT. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterol 2016;16:50. [PMID: 27117280 DOI: 10.1186/s12876-016-0464-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
23 Wang MH, Ji Y, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Bi AH, Tan YS. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. Int J Radiat Oncol Biol Phys 2010;76:467-76. [PMID: 19406586 DOI: 10.1016/j.ijrobp.2009.01.057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
24 Yeh JH, Hung CH, Wang JH, Chen CH, Kee KM, Kuo CM, Yen YH, Cheng YF, Chen YY, Hsu HC, Lu SN. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLoS One 2015;10:e0144893. [PMID: 26661388 DOI: 10.1371/journal.pone.0144893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 2020;19:108-30. [PMID: 32038120 DOI: 10.17179/excli2019-1842] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
26 Kao CC, Chen MK, Kuo WH, Chen TY, Su SC, Hsieh YH, Liu CL, Chou MC, Tsai HT, Yang SF. Influence of glutathione-S-transferase theta (GSTT1) and micro (GSTM1) gene polymorphisms on the susceptibility of hepatocellular carcinoma in Taiwan. J Surg Oncol 2010;102:301-7. [PMID: 20672314 DOI: 10.1002/jso.21643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Li H, Wu JS, Wang XT, Lv P, Gong LS, Liu G, Tian BN, Li YY, Jiang B. Factors predicting surgical resection in patients with intrahepatic cholangiocarcinoma and cirrhosis. J Invest Surg 2014;27:219-25. [PMID: 24476002 DOI: 10.3109/08941939.2014.880138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
28 Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M, Sasaki Y. Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 2010;45:60-7. [DOI: 10.1007/s00535-009-0109-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
29 Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
30 Gon H, Kido M, Tanaka M, Kinoshita H, Komatsu S, Tsugawa D, Awazu M, Toyama H, Matsumoto I, Itoh T, Fukumoto T. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. Surgery 2018;164:1014-22. [DOI: 10.1016/j.surg.2018.06.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford) 2013;15:985-90. [PMID: 23607636 DOI: 10.1111/hpb.12080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
32 Tsai HJ, Hsieh MY, Tsai YC, Liu ZY, Hsieh HY, Lee CM, Chien CH, Chiu YW, Chuang HY, Huang CT. Liver function tests may be useful tools for advanced cancer patient care: a preliminary single-center result. Kaohsiung J Med Sci 2014;30:146-52. [PMID: 24581215 DOI: 10.1016/j.kjms.2013.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
33 Yen Y, Changchien C, Wang J, Kee K, Hung C, Hu T, Lee C, Lin C, Wang C, Chen T, Huang Y, Lu S. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Digestive and Liver Disease 2009;41:431-41. [DOI: 10.1016/j.dld.2008.11.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
34 Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol 2014;41:415-21. [PMID: 25023358 DOI: 10.1053/j.seminoncol.2014.04.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
35 Tseng CH. Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan. Hepatol Int. 2013;7:693-702. [PMID: 26201803 DOI: 10.1007/s12072-012-9405-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
36 Kee KM, Wang JH, Wang CC, Cheng YF, Lu SN. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival. Sci Rep 2016;6:30156. [PMID: 27444261 DOI: 10.1038/srep30156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
37 Ahn HS, Han SH, Kim YH, Park BJ, Kim DH, Lee JB, Park SY, Song CS, Lee SW, Choi C, Myoung J, Choi IS. Adverse fetal outcomes in pregnant rabbits experimentally infected with rabbit hepatitis E virus. Virology 2017;512:187-93. [PMID: 28982029 DOI: 10.1016/j.virol.2017.09.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
38 Zahran AM, Zahran ZAM, El-Badawy O, Abdel-Rahim MH, Ali WAM, Rayan A, Abbas El-Masry M, Abozaid MAA, Hetta HF. Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. Immunol Res 2019;67:157-65. [PMID: 31028612 DOI: 10.1007/s12026-019-09075-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
39 Yu MC, Chan KM, Lee CF, Lee YS, Eldeen FZ, Chou HS, Lee WC, Chen MF. Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? J Gastrointest Surg. 2011;15:1440-1449. [PMID: 21541770 DOI: 10.1007/s11605-011-1537-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
40 Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009;5:889-899. [PMID: 19663737 DOI: 10.2217/fon.09.64] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
41 Zhang XP, Gao YZ, Jiang YB, Wang K, Chen ZH, Guo WX, Shi J, Zhang YJ, Chen MS, Lau WY, Cheng SQ. A serological scoring system to predict lymph node metastasis in patients with hepatocellular carcinoma. HPB (Oxford) 2019;21:335-44. [PMID: 30104175 DOI: 10.1016/j.hpb.2018.07.013] [Reference Citation Analysis]
42 Chang CC, Chen SC, Hsieh YH, Chen YC, Chen TY, Chu YH, Ma HJ, Chou MC, Tsai HT, Yang SF. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med 2009;47:412-8. [PMID: 19327121 DOI: 10.1515/CCLM.2009.092] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
43 Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G, Dominguez S. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012;56:1080-1088. [PMID: 22245896 DOI: 10.1016/j.jhep.2011.12.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 6.6] [Reference Citation Analysis]
44 Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ. Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). Hepatol Commun 2017;1:736-47. [PMID: 29404490 DOI: 10.1002/hep4.1073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
45 Chang PY, Huang CC, Hung CH, Yu CY, Wu DK, Hwang JI, Liang PC, Wu RH, Tsai WL, Lin YJ, Liu YS, Liang HL, Lee RC, Chen CH. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. Liver Cancer 2018;7:312-22. [PMID: 30488021 DOI: 10.1159/000487608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Fukumoto T, Kido M, Takebe A, Tanaka M, Kinoshita H, Kuramitsu K, Komatsu S, Tsugawa D, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today. 2017;47:1094-1103. [PMID: 28324163 DOI: 10.1007/s00595-017-1507-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]